Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
OBJECTIVE
The authors examined the efficacy, tolerability, and safety of ondansetron, a selective serotonin 3 receptor antagonist, in patients with tardive dyskinesia.


METHODS
Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study.


RESULTS
Administration of ondansetron resulted in a statistically significant improvement in tardive dyskinesia and psychotic symptoms.


CONCLUSIONS
Ondansetron may be an effective and safe therapy to control tardive dyskinesia and psychosis in patients with schizophrenia.
Sirota
P
P
Abarbanel Mental Health Center, Bat Yam, Israel. psrt1a@netvision.net.il
Mosheva
T
T
Shabtay
H
H
Giladi
N
N
Korczyn
A D
AD
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D012702:Serotonin Antagonists; D017294:Ondansetron